Drug Trial Radar · NCT06732180
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease
Last checked: Nov 20, 2026Latest source record: May 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Feb 21, 2025
Primary completion
Nov 30, 2025
Study completion Nov 30, 2025
Sponsor
- Lead sponsor
- Gain Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 30 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main goal of this clinical trial is to learn about the safety and tolerability of GT-02287. The questions it aims to answer are: * What medical problems do participants have when taking GT-02287? * How is GT-02287 absorbed, distributed, and removed from the body of participants over time (pharmacokinetics)? * Are there any biological effects of GT-02287 in blood and in cerebrospinal fluid that could be beneficial for people with Parkinson's disease? Participants will: * visit the clinic to assess if they qualify for the study (30-day Screening Period) * if eligible, receive GT-02287 once a day every day for 90 days (90-day Open Label Treatment period) * visit the clinic the first day of treatment, after the first 2 weeks of treatment, and every month during the 90-day Treatment Period. * visit the clinic to assess how they are doing 14 days after the end of GT-02287 treatment (14-day Follow-Up Period).
Conditions
- Parkinson Disease
Interventions
GT-02287Drug
Dose of 13.5 mg/kg/day (plus/minus 2 mg/kg/day based on body weight) to be administered orally once a day for 90 days. Dosage form: powder in sachet (200 mg of GT-02287 per sachet) for reconstitution with a suspending agent
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence, nature, relationship to investigational product (IP), and severity of adverse events (AEs)Time frame: From first dose to Day 105
- Incidence of clinically significant findings for clinical laboratory evaluations, physical and neurological examinations, body weight , vital signs measurements, 12-lead o 12-lead electrocardiograms (ECGs), Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: From first dose to Day 105
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
St Vincent's Hospital Sydney
Darlinghurst, New South Wales, Australia · Recruiting
Southern Neurology
Kogarah, New South Wales, Australia · Recruiting
Westmead Hospital
Westmead, New South Wales, Australia · Recruiting
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia · Recruiting
CMAX
Adelaide, South Australia, Australia · Recruiting
Alfred Health
Melbourne, Victoria, Australia · Recruiting
Royal Melbourne Hospital
Parkville, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.